Swiss pharmaceutical giant Roche (SWX: ROG) has announced that the National Medical Products Administration (NMPA) has approved the 300mg dosage regimen of Cosentyx (secukinumab) for use in treating ankylosing spondylitis (AS). This approval represents a significant advancement in the management of this chronic inflammatory disease.
Approval Based on MEASURE 3 Study Results
The new dosage approval is based on the results of the MEASURE 3 study, which demonstrated that the 300mg dose of Cosentyx effectively improved the symptoms of AS patients, with effects lasting for up to three years. Importantly, the safety profile of the 300mg dosage was found to be comparable to that of the previously established 150mg dose.
Reduced Injection Frequency for Patients
Cosentyx’s recommended 300mg dosage involves subcutaneous injections at weeks 0, 1, 2, 3, and 4, followed by maintenance doses of 300mg every four weeks. The introduction of the 300mg single injection significantly reduces the number of injections required, enhancing patient convenience and adherence to treatment.-Fineline Info & Tech
